LSE - Delayed Quote EUR

Faes Farma, S.A. (0K9H.L)

Compare
4.0750 -0.0150 (-0.37%)
At close: July 21 at 5:31 PM GMT+1
Loading Chart for 0K9H.L
DELL
  • Previous Close 4.0900
  • Open 4.1250
  • Bid --
  • Ask --
  • Day's Range 4.0950 - 4.1050
  • 52 Week Range 3.0400 - 4.1050
  • Volume 1,024
  • Avg. Volume 19,066
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date Jul 26, 2024 - Jul 30, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials worldwide. It operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. It offers products for various therapeutic areas. The company also provides animal nutrition and health products. Faes Farma, S.A. was incorporated in 1933 and is headquartered in Leioa, Spain.

faesfarma.com

1,748

Full Time Employees

December 31

Fiscal Year Ends

--

Sector

--

Industry

Recent News: 0K9H.L

View More

Performance Overview: 0K9H.L

Trailing total returns as of 6/28/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

0K9H.L
29.91%
MSCI WORLD
10.81%

1-Year Return

0K9H.L
32.78%
MSCI WORLD
20.22%

3-Year Return

0K9H.L
30.77%
MSCI WORLD
0.00%

5-Year Return

0K9H.L
19.76%
MSCI WORLD
62.09%

Compare To: 0K9H.L

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 0K9H.L

View More

Valuation Measures

Annual
As of
  • Market Cap

    --

  • Enterprise Value

    --

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.66%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    14.93%

  • Revenue (ttm)

    482.06M

  • Net Income Avi to Common (ttm)

    94.75M

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    47.75M

  • Total Debt/Equity (mrq)

    4.22%

  • Levered Free Cash Flow (ttm)

    --

Research Analysis: 0K9H.L

View More

Company Insights: 0K9H.L

Research Reports: 0K9H.L

View More